Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,172 matching trials from the live ClinicalTrials.gov search.
Filters: "amyloid" Clear all
Completed Phase 1 Interventional Results available

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

NCT01736696
View directory record Official record
Conditions
Psoriasis, Immunomodulation
Interventions
tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting Not applicable Interventional

Developing a Digital Aid to Improve ICD Decisions

NCT07084142
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction
Interventions
Online, patient-facing decision-making aid (app) with personalized risk information., Implantable Cardioverter Defibrillator (ICD), Online, patient-facing decision-making app without personalized risk information.
Other · Device
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
San Francisco, California • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)

NCT06597942
View directory record Official record
Conditions
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease, Moderate Alzheimer&Amp;Amp;#39;s Disease, Alzheimer&Amp;#39;s Disease (AD), Alzheimer&Amp;#39;s Dementia
Interventions
TMS, Transcranial Magnetic Stimulation Sham
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 2, 2026, 2:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 2, 2026, 2:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers

NCT00952185
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm, Viral Infection
Interventions
cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

NCT00288704
View directory record Official record
Conditions
Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions
rilonacept 160 mg, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
24
States / cities
Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

NCT02061878
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
ReXceptor, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

NCT01570387
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Pomalidomide, Dexamethasone
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adaptation in Polyphenol Bioavailability and Bioactivity During Long Term Exposure to Polyphenol-Rich Foods

NCT02197754
View directory record Official record
Conditions
Healthy
Interventions
Controlled diet
Other
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
25 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

NCT03821857
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18-F-Flortaucipir
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

NCT07651319
View directory record Official record
Conditions
Alzheimer Dementia (AD)
Interventions
IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 86 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting No phase listed Observational

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

NCT06566170
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Usual Care
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 2, 2026, 2:49 PM EDT
Completed No phase listed Observational

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients

NCT01213641
View directory record Official record
Conditions
Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS), Muckle-wells Syn (MWS), Neonatal Onset Multisystem Inflam Disease (NOMID)
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Little Rock, Arizona • Columbus, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 2, 2026, 2:49 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers

NCT05601856
View directory record Official record
Conditions
Alzheimer Disease, Gut Biome
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years to 90 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

NCT00694161
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Fx-1006A
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 2, 2026, 2:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Brain Aging in Vietnam War Veterans

NCT01687153
View directory record Official record
Conditions
Traumatic Brain Injury, Post Traumatic Stress Disorder, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 90 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
19
States / cities
Sun City, Arizona • Irvine, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 2, 2026, 2:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Sleep Amyloid, Slow WAve Race and Ethnicity Study

NCT03814603
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PET-MR Scan, PiB
Procedure · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Not applicable Interventional Results available

Evaluating the Effect of Tooth Cleaning Devices on Oral Health

NCT01250769
View directory record Official record
Conditions
Dental Plaque
Interventions
Manual Toothbrush, Interproximal Cleaning Device
Device
Lead sponsor
Philips Oral Healthcare
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 2, 2026, 2:49 PM EDT
Terminated No phase listed Observational

Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial

NCT02781220
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

NCT07075510
View directory record Official record
Conditions
Plasma Cell Disorder
Interventions
Daratumumab Injection
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy

NCT01855360
View directory record Official record
Conditions
Amyloidosis; Heart (Manifestation), Senile Cardiac Amyloidosis
Interventions
Tauroursodeoxycholic Acid and Doxycycline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 2, 2026, 2:49 PM EDT
Recruiting Phase 2 Interventional

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

NCT06489548
View directory record Official record
Conditions
Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 2, 2026, 2:49 PM EDT
Completed Not applicable Interventional Results available

Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety

NCT02497755
View directory record Official record
Conditions
Anxiety, Depression
Interventions
App for smartphone, smartphone
Behavioral · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 2, 2026, 2:49 PM EDT
No Longer Available No phase listed Expanded access

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00423826
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 2, 2026, 2:49 PM EDT